Особенности фармакокинетики фексофенадина при совместном применении с верипамилом и негрустином
Диссертация
Определено содержание фексофенадина в плазме крови добровольцев и лабораторных животных до и после курсового приема экстракта зверобоя. Отмечено статистически достоверное снижение максимальной концентрации фексофенадина после приема экстракта зверобоя в 2,4 раза (р < 0,05) и в 2,2 раза (р < 0,001) у кроликов и у пациентов соответственно. У пациентов наблюдалось статистически достоверное… Читать ещё >
Список литературы
- Белоусов Ю.Б., Леонова М. В. Введение в клиническую фармакологию. -М.:МИА, 2002.- 128 с.
- Бидлингмейер Б. Препаративная жидкостная хроматография. Пер. с англ. М.: Мир, 1990. — 360 с.
- Витамины и микроэлементы в клинической фармакологии / Под ред. акад. РАМН, проф. В. А. Тутельяна. -М.: Паля-М, 2001. 560 с.
- Высокоэффективная жидкостная хроматография в биохимии. / Г. Бауэр, X. Энгельгард, А. Хеншен и др. Пер. с англ. М.: Мир, 1988. — 688 с.
- Зенкевич И.Г., Косман В. М. Методы количественного хроматографии-ческого анализа лекарственных веществ. // Методическое указание. — СПХФА, 1999.-80 с.
- Коровина Н.А. Применение мультивитаминов для восполнения дефицита витаминов группы В. // Фармацевтический вестник. 2003. — № 34. — С. 34−35.
- Кукес В.Г., Стародубцев А. К. Клиническая фармакология и фармакотерапия. М.: ГЭОТАР-МЕД, 2003. — 640 с.
- Молекулярные механизмы взаимодействия лекарственных средств. / Под ред. Пальцева М. А., Кукеса В. Г., Фисенко В.П.— М.: АстраФармаСервис. -2004. — 224 с.
- Новиков А.Г., Логунова З. В., Потекаев Н. Н. Фексофенадин в терапии хронической идиопатической крапивницы. // Клиническая дерматология и венерология. 2003. — № 2 — С. 53 — 54.
- Орлов В.И., Аратсков А. А. Жидкостная хроматография. Теоретические основы. Дзержинск, 1997.
- Основы клинической фармакологии и рациональной фармакотерапии. / Под ред. Ю. Б. Белоусова, М. В. Леоновой. — М.: Бионика. 2002. — 357 с.
- Остроумова О.Д., Батурина A.M., Зыкова А. А. / Лекарственное взаимодействие: существуют ли «идеальные» лекарственные препараты для использования в условиях полипрагмазии? // Русский медицинский журнал. -2003.-т. 11.-№ 21.-С. 43−50.
- Рудаков О.Б. Растворитель как средство управления процессом в жидкостной хроматографии. Воронеж: ВГУ, 2003. — 300 с.
- Сидорова Т. А., Солнцева Т. И. Р-гликопротеин — АТФ-аза с конститутивной активностью. // Биологические мембраны. — 2003. — т. 20. -№ 3. С. 225−235.
- Ставровская А.А. Опухолевая клетка в обороне. // Соросовский образовательный журнал. 2001. — т. 7. — № 7. — С. 17—23.
- Стромская Т.П., Рыбалкина Е. Ю. Множественная лекарственная устойчивость опухолевых клеток, обусловленная Р-гликопротеином, и их дифференцировка. // Биологические мембраны. 2003. — т. 20. — № 3. — С. 244−255.
- Стыскин Е.Л., Ициксон Л. Б., Брауде Е. В. / Практическая высокоэффективная жидкостная хроматография. М.: Химия, 1986. — 214 с.
- Федосеев Г. Б., Зинакова М. К., Ровкина Е. И. Клинические испытания препарата фексадин (фексофенадин). // Иммунология. 2004. — № 4 (172). -С. 19−21.
- Шатц В.Д., Сахартова О. В. Высокоэффективная жидкостная хроматография. Основы теории. Методология. Применение в лекарственной химии. Рига: Зинатне, 1988. — 390 с.
- Abbas M.N., Abdel Fattah A.A., Zahran E. A novel membrane sensor for histamine HI-receptor antagonist «Fexofenadine». // Analytical Sciences. 2004. -Vol.2. -P.l 137−1142.
- Analysis of drug permeation across caco-2 monolayer: Implication for predicting in vivo drug absorption. / S. Yamashita, Y. Tanaka, Y. Endoh et al. // Pharmaceutical research. 1997. — No. 14. — P. 486 — 491.
- Bain L.J., McLachlan J.B., LeBlanc G.A. Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. // Environmental Health Perspectives. 1997. — Vol. 105. — No. 8. — P. 812 — 818.
- Barrientos A.R.E. The determination of Fexofenadine in Human Plasma by LC-MS/MS using Cetirizine as the Internal Standard. // SOP Number: 27/01. -Current version issued at: 30.05.2003. Institute of biomedical sciences. — P. 8 — 12.
- Beaird S.L. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. // Journal of the American pharmacists association. 2000. — No. 40. — P. 637 — 644.
- Biochemical, cellular and pharmacological aspects of the multidrug transporter. / S. V Ambudkar, S. Dey, C.A. Hrycyna et al. // Annual Review of Pharmacology and Toxicology. 1999. -No. 39. — P. 361 — 398.
- Cellular localization of the multidrug resistance gene product in normal human tissues. / F. Thiebaut, T. Tsuruo, H. Hamada et al. // Proceedings of the National Academy of Sciences, USA. 1987. — No. 84. — P. 7735 — 7738.
- Characterization of the Major Metabolites of Verapamil as Substrates and Inhibitors of P-glycoprotein. / C. Pauli-Magnus, O. Richter, O. Burk et al. // Journal of Pharmacology and Experimental Therapeutics. 2000. — Vol. 293. — No. 2.-P. 376−382.
- Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in caco-2 cells. / V.D. Makhey, A. Guo, D.A. Norris et al. // Pharmaceutical research. 1998. — No. 15. — P. 1160 — 1167.
- Chiou W.L., Chung S.M., Wu T.C. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. // Pharmacological Research. 2000. — No. 17. — P. 205 — 208.
- Cisapride (cis) is an inhibitor but not a substrate for human P-glycoprotein. / S.M. Abdel-Rahman, L. Lan, K. Yasuda et al. // Clinical pharmacology and therapeutics. 2000. — No. 67. — P. 1 — 34.
- Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. / Y. Adachi, H. Suzuki, Y. Sugiyama. // Pharmacological Research.-2001.-No. 18.-P. 1660- 1668.
- Determination of fexofenadine in human plasma and urine by liquid chromatography mass spectrometry. / U. Hoffmann, M. Seiler, S. Drescher and
- F. Fromm. // Clinical Pharmacology and Therapeutics. 1998. — Vol. 64. — No. 6. -P. 612−621.
- Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. / A.H. Schinkel, J.J.M. Smit, O. van Tellingen et al. // Cell. 1994. — No. 77. — P. 491 — 502.
- Drug/Metabolic pairs: Comparison of their affinities to intestinal P-glycoprotein. / C. Dressier, A. Hanafy, S. Neuhoff et al. // Poster Jahrestagung der Deutschen Pharmazeutischen Gesellschaft. Archiv der Phamazie. 2000. — Vol. 2. -No. 333.-P. 42.
- Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. / S. Song, H. Suzuki, R. Kawai and Y. Sugiyama. // Drug metabolism and disposition. 1999. — No. 27. — P. 689−694.
- Effects of Hypericum Extract (LI 160) on the Change of Auditory Evoked Potentials by Cortisol Administration. / H. Murck, M. Uhr, K. Schaffler and K. Seibel. // Biological Psychiatry. 2004. — Vol. 50. -No. 2. — P. 128 — 133.
- Examination of the Functional Activity of P-glycoprotein in the Rat Placental Barrier Using Rhodamine 123. / P. Pavek, F. Staud, Z. Fendrich et al. // Journal of Pharmacology and Experimental Therapeutics. 2003. — No. 305. — P. 1239 -1250.
- Fardel O., Lecureur V., Guillouzo A. The P-glycoprotein multidrug transporter. // General Pharmacology. 1996. — Vol. 27. — No. 8. — P. 1283 — 1291.
- Fromm M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. // International Journal of Clinical Pharmacology and Therapeutics. Vol. 38. — P. 69 — 74.
- Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. / G.K. Dresser, D.G. Bailey, B.F. Leake et al. // Clinical Pharmacology and Therapeutics. 2002. — No. 71.-P. 11−20.
- Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. I I Drug Safety. 1998. — No. 18. — P. 251 — 272.
- Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human. / T. Nozawa, K. Imai, J.-I. Nezu et al. // The Journal of Pharmacology and Experimental Therapeutics. 2004. — No. 308. -P.438 — 445.
- Gottesman M.M., Pastan I., Ambudkar S.V. P-glycoprotein and multidrug resistance. // Current Opinion of Genetic Devices. 1996. — No. 6. — P. 610 — 617.
- Glycoprotein-Mediated Transport of Itraconazole across the Blood-Brain Barrier. / T. Miyama, H. Takanaga, H. Matsuo etc. // Antimicrobial Agents and Chemotherapy. 1998. — Vol. 42. — No. 7. — P. 1738 — 1744.
- Grapefruit juice felodipine interaction: mechanism, predictability and effect of naringin. / D.G. Bailey, J.M.O. Arnold, J.R. Bend et al. // Clinical Pharmacology and Therapeutics. — 1993. — No. 53. — P. 637−642.
- Growth inhibition, cytokinesis failure and apoptosis of multidrug resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. / G. Lehne, P. De Angelis, D.M. Boer and H.E. Rugstad. // Leukemia. 1999. — No. 13. — P. 768 -778.
- HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. / J. Drewe, H. Gutmann, G. Fricker etal. // Journal of biochemistry and pharmacology. 1999. — No. 57. — P. 1147 -1152.
- Impact of Drug Transporter Studies on Drug Discovery and Development. / N. Mizuno, T. Niwa, Y. Yotsumoto, Y. Sugiyama. // Pharmacological Review. -2003.-No. 55.-P. 425−461.
- Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. / R.J. Sokol, K.E. Johnson, F.M. Karrer et al. // Lancet. 1991. — No. 338. — P. 212 — 214.
- In Vitro and In Vivo Evaluations of Intestinal Barriers for the Zwitterion L-767,679 and Its Carboxyl Ester Prodrug L-775,318. / T. Prueksaritanont, P. DeLuna, L.M. Gorham et al. // Roles of Efflux and Metabolism. 1998. — Vol. 26. -No. 6.-P. 520−527.
- Increased drug delivery to the brain by P-glycoprotein inhibition. / J.M. Sadeque, C. Wandel, H. He et al. // Clinical Pharmacology and Therapeutics. -2000. No. 68. — P. 231 — 237.
- Indinavir concentrations and St John’s Wort. / S.C. Piscitelli, A.H. Burstein, D. Chaitt et al. // Lancet. 2000. — No. 355. — P. 547 — 548.
- Induction of P-glycoprotein and Cytochrome P450 ЗА by HIV Protease Inhibitors. L. Huang, S.A. Wring, J.L. Wolley et al. // Drug Metabolism and Disposition.-2001.-Vol. 29.-No. 5.-P. 754−760.
- Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. M. Demeule, A. Laplante, A. Sepehr-Arae et al. // Biochemistry and Cell Biology. -1999.-Vol. 77.-P. 47−58.
- Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. / H. Takanaga, A. Ohnishi, H. Matsuo, Y. Sawada. // Biological and Pharmaceutical Bulletin. 1998. — No. 21. — P. 1062 — 1066.
- Interaction between grapefruit juice and midazolam in humans. / H.H. Kupferschmidt, H.R. Ha, W.H. Ziegler // Clinical Pharmacology and Therapeutics. -1995.-No. 58.-P. 80−81.
- Ito K., Kusuhara H., Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. // Pharmacological Research. 1999. — No. 16. — P. 225 — 231.
- Johnstone R.W., Cretney E., Smyth M.J. P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell Death. // Blood. 1999. — Vol. 93. — No. 3. — P. 1075 — 1085.
- Johnston A., Holt D. Effect of grapefruit juice on blood cyclosporin concentration. // Lancet. 1995. — No. 346. — P. 122 — 123.
- Kanazawa S., Ohkubo Т., Sugawara K. The effects of grapefruit juice on the pharmacokinetics of erythromycin. // European Journal of Clinical Pharmacology. 2001. — No. 56. — P. 799 — 803.
- Lee C.G.L., Gottesman M.M. HIV-l protease inhibitors and the MDR1 multidrug transporter. // Journal of Clinical Investigations. 1998. — No. 101. — P. 287 — 288.
- Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. / T. Uno, N. Yasui-Furukori, T. Takahata et al. // Journal of Pharmaceutical and Biomedical Analysis. 2004. — Vol. 35. — No. 4. — P. 937 -942.
- Liu R., Sharom F.J. Fluorescence studies on the nucleotide binding domains of the P-glycoprotein multidrug transporter. // Biochemistry. 1997. — Vol. 36. — P. 2836 — 2843.
- Lo Y.L., Hsu C.Y., Huang J.D. Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line. // Anticancer Research. No. 18. — P. 3005 — 3009.
- Loo T.W., Clarke D.M. Identification of residues in the drug-binding domain of human P-glycoprotein. // Journal of Biological Chemistry. 1999. — No. 50. — P. 35 388−35 392.
- Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. / L. Becquemont, M. Camus, V. Eschwege et al. // Fundamental and clinical pharmacology. 2000. — No. 14. — P. 519 — 525.
- Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase С blockers. A.F. Castro, J.K. Horton, C.G. Vanoye, G.A. Altenberg. // Biochemical Pharmacology. 1999. — No. 58. — P. 1723 — 1733.
- Mitochondria-Targeting Drug Oligomycin Blocked P-glycoprotein Activity and Triggered Apoptosis in Doxorubicin-Resistant HepG2 Cells. / Y.C. Li, K.P. Fung, T.T. Kwok et al. // Chemotherapy. 2004. — Vol. 50. — No. 4. — P. 55 — 62.
- Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. / B.I. Sikic, G.A. Fisher, B.L. Lum etc. // Cancer Chemotherapy and Pharmacology. 1997. — No. 40. — P. 13 — 19.
- Molecular and physical mechanisms of first-pass extraction. / S.D. Hall, K.E. Thummel, P.B. Watkins et al. // Drug Metabolism and Disposition. 1999. — No. 27.-P. 161 — 166.
- Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. C. Tannergren, N. Petri, L. Knutson et al. // Clinical Pharmacology and Therapeutics. 2003. — Vol. 74. — No. 5. — P. 423 -456.
- OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. / M. Cvetkovic, B. Leake, M.F. Fromm et al. // Drug Metabolism and Disposition. 1999. — No. 27. — P. 866 — 871.
- P-glycoprotein and cytochrome P-450 ЗА inhibition: dissociation of inhibitory potencies. / C. Wandel, R.B. Kim, S. Kajiji et al. // Cancer Research. -1999. No. 59. — P. 3944 — 3948.
- P-glycoprotein and surfactants: Effect on intestinal talinolol absorption. / K. Bogman, Y. Zysset, L. Degen et al. // Clinical Pharmacology and Therapeutics. -2005.-Vol. 77.-No. l.-P. 24−32.
- P-glycoprotein expression and function in circulating blood cells from normal volunteers. / W.T. Klimecki, B.W. Futscher, T.M. Grogan and W.S. Dalton. // Blood. 1994. — No. 83. — P. 2451 — 2458.
- P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. / U.I. Schwarz, T. Gramatte, J. Krappweis et al. // International Journal of Clinical Pharmacology and Therapeutics. 2000. — No. 8. -P. 161 — 167.
- Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). / A. Johne, J. Brockmoller, S. Bauer et al. // Clinical Pharmacology and Therapeutics. 199. — No. 66. — P. 338 — 345.
- Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-l protease inhibitors into brain and testes. / E.F. Choo, B. Leake, C. Wandel et al. // Drug Metabolism and Disposition. 2000. — No. 28. — P. 655 — 660.
- Pharmacology, 4th edition. / H.P. Rang, M.M. Dale, J.M. Ritter, P.K. Moore. -Edinburgh, 1999.
- Pharmacology, 5th edition. / H.P. Rang, M.M. Dale, J.M. Ritter, P.K. Moore. -Edinburgh, 2003.
- Potschka H., Loscher W. In Vivo Evidence for P-Glycoprotein-Mediated Transport of Phenytoin at the Blood-Brain Barrier of Rats. // Epilepsia. 2001. -Vol. 42.-No. 10.-P. 1231.
- Preiss R. P-glycoprotein and related transporters. // International Journal of Clinical Pharmacology and Therapeutics. 1998. — No. 36. — P. 3 — 8.
- Projection structure of P-glycoprotein by electron microscopy. / J.-Y. Lee, I.L. Urbatsch, A.E. Senior, et al. // Journal Biological Chemistry. 2002. — Vol. 277. — No. 42.-P. 40 125−40 131.
- Radhakrishna Т., Om Reddy G. Simultaneous determination of fexofenadine and its related compounds by HPLC. // Journal Pharmacology and Biomedical Analyses. 2002. — Vol. 29. — No. 4. — P. 681 — 690.
- Randolph G.J., Beaulieu S., Pope M. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. // Immunology. 1998. — Vol. 95. — No. 12. — P. 6924 -6929.
- Reversal of P-glycoprotein-mediated multidrug resistance in vitro by antihistamines and diuretics. / A. Aszalos, S. Ibrahim, A. Knapton and T. Licht. // Clinical Pharmacology and Therapeutics. 2000. — No. 67. — P. 1−70.
- Roberts S.A. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. // Xenobiotica. 2001. — No. 31. — P. 557 — 589.
- Romac D.R., Albertson Т.Е. Drug interactions in the intensive care unit. // Clinics in Chest Medicine. 1999. — Vol. 20. — No. 2. — P. 385 — 399.
- Romsicki Y., Sharom FJ. / The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. // Biochemistry. — 1999. -No. 38.-P. 6887−6896.
- Sadek P.C. Troubleshooting HPLC Systems: A Bench Manual. Wiley-Interscience. — 1999. 306 p.
- Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordiantely up-regulates these proteins in human colon carcinoma cells. // Molecular Pharmacology. 1996. — No. 49. — P. 311−318.
- Seelig A., Blatter L.X., Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. // International Journal of Clinical Pharmacology and Therapeutics. 2000. — No. 38.-P. Ill — 121.
- Simons F.E.R., Silver N.A. Clinical pharmacology of HI-antihistamines in the skin. // Journal Allergy and Clinical Immunology. 2002. — Vol. 110. — No. 5. — P. 787−783.
- Smit J.J.M., Schinkel A.H., Oude Elferink R.P.J. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. // Cell. 1993. — Vol. 75. — No. 3. — P. 451 — 462.
- Snyder L. R, Kirkland J.J., Glajch J.L. Practical HPLC Method Development, 2nd Edition. Wiley-Interscience. — 1997. — 765 p.
- Spahn-Langguth H., Langguth P. Grapefruit juice enhancs intestinal absorption of the P-glycoprotein substrate talinolol. // European Journal of Pharmaceutical Sciences. 2001. — No. 12. — P. 361 — 367.
- St. John’s wort induces intestinal P-glycoprotein/MDRl and intestinal and hepatic CYP3A4. / D. Durr, B. Stieger, G.A. Kullak-Ublick et al. // Clinical Pharmacology and Therapeutics. 2000. — Vol. 68. — P. 598 — 604.
- Stein W.D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. / Physiological Review. 1997. — No. 77. — P. 545 — 590.
- Sukhai M., Yong A., Piquette-Miller M. Concentration dependent effects of interleukin (IL)-l and IL-6 on expression of P-glycoprotein in cultured hepatocytes. // Clinical Pharmacology and Therapeutics. 2000. — No. 67. — P. 41 -48.
- Tamai I., Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. // Journal of pharmaceutical sciences. 2000. — No. 89. — P. 1371 -1388.
- Terhechte A., Blaschke G. Investigation of the stereoselective metabolism of the chiral Hl-antihistaminic drug terfenadine by high performance liquid chromatography. // Journal of Chromatography A. 1995. — Vol. 694. — P. 219 — 225.
- The Drug Transporter P-glycoprotein Limits Oral Absorption and Brain Entry of HIV-1 Protease Inhibitors. / R.B. Kim, M.F. Fromm, C. Wandel et al. // Journal of Clinical Investigations. 1998. — Vol. 101. — No. 2. — P. 289 — 294.
- The effect of rifampin administration on the disposition of fexofenadine. / M.A. Hamman, M.A. Bruce, B.D. Haehner-Daniels et al. // Clinical Pharmacology and Therapeutics.-2001.-Vol. 69.-No. 3.-P. 114 121.
- The multidrug resistance protein family. P. Borst, R. Evers, M. Kool, J. Wijnholds. // Biochimica et Biophysica Acta. 1999. — No. 1461. — P. 347 — 357.
- The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. Eichelbaum M., Greiner В., Fritz P. et al. // Journal of Clinical Investigations. -1999. -No. 104.-P. 147- 153.
- The role of P-glycoprotein in drug disposition: significance to drug development. / M.D. Troutman, G. Luo, L.S. Gan, D.R. Thakker. // Drug-Drug Interactions. Dekker, Marcel Incorporated. — 2001. — 650 p.
- Tissue distribution of the human MDR3 P-glycoprotein. / J.J. Smit, A.H. Shinkel, C.A. Mol et al. // Laboratory Investigations. 1994. — Vol. 71. — No. 5. -P. 638 — 649.
- Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: Analysis of lymphocyte surface expression and drug-unrelated function. / M.B. Lucia, R. Cauda, A.L. Landay et al. // AIDS Research and Human Retroviruses. — 1995. -No. 11.-P. 893 -901.
- United States Pharmacopea. 29th edn. — P. 905.
- Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. / L. Yu, A. Bridgers, J. Polli et al. // Pharmaceutical Research. 1999. — No. 16. — P. 1812 — 1817.
- Wacher V.J., Salphati L., Benet L.Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. // Advanced Drug Delivery Reviews. -2001.-No. 46.-P. 89−102.
- White R.E. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. // Annual Review of Pharmacology and Toxicology. 2000. — No. 40. — P. 133 — 157.
- Wysowski D.K., Bacsanyi J. Cisapride and fatal arrhythmia. // National English Journal of Medicine. 1996. — No. 35. — P. 290 — 291.
- Yu D.K. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. // Journal of Clinical Pharmacology. 1999. — No. 39. — P. 12 031 211.
- Zhang Y., Benet L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 ЗА and P-glycoprotein. // Clinical Pharmacokinetics. 2001. -No. 40.-P. 159- 168.
- Zuylen L.V., Verweij J., Sparreboom A. Role of formulation vehicles in taxane pharmacology. // Investigational new drugs. 2001. — No. 19. — P. 125 -141.